| outer membrane protein d2 catalyzes facilitated diffusion of carbapenems and penems through the outer membrane of pseudomonas aeruginosa. | the outer membrane of imipenem-resistant mutants of pseudomonas aeruginosa with decreased permeability to imipenem was shown by western (immuno-) blotting to contain protein d1 and to lack protein d2. protein d2 was purified and was shown to allow the permeation of imipenem at a rate higher than expected from its molecular weight. spontaneous imipenem-resistant mutants of p. aeruginosa pao1 appeared at a frequency of 10(-8) in the laboratory and did not synthesize protein d2. experiments perform ... | 1990 | 2109575 |
| antimicrobial resistance in the intensive care unit. | antimicrobial resistance remains a major clinical problem in the intensive care unit despite the introduction of potent new antibiotics and the application of infection control measures. impaired antibiotic permeability, antibiotic inactivation and alteration of antibiotic target sites, typically in concert, are mechanisms by which this resistance occurs. resistance traits may be chromosomally mediated, in which case they may be expressed constitutively or inducibly, or may be mediated by plasmi ... | 1990 | 2123990 |
| multicenter in vitro comparison of piperacillin and nine other antibacterials against 1,629 clinical isolates. | the antibacterial spectrum of activity of piperacillin was compared with that of other antibiotics against isolates of escherichia coli, enterobacter cloacae, haemophilus influenzae, klebsiella pneumoniae, pseudomonas aeruginosa, pseudomonas cepacia, pseudomonas maltophilia, serratia marcescens, enterococcus sp, bacteroides fragilis, bacteroides bivius, and clostridium difficile obtained from laboratories at hospitals in st. louis, in memphis, and in newark, new jersey. of the 1,629 isolates tes ... | 1990 | 2183941 |
| [characterization of telluric bacteria attributable to pseudomonas maltophilia]. | the taxonomic position of some telluric non-fermenting gram-negative bacteria collected into a phenon representing about a quarter of the soil isolates by an earlier numerical analysis is specified. the shapiro--chargaff coefficient determined by thermal-transition curves of the dna and their hybridization by nitrocellulose filters method show a close affinity with pseudomonas maltophilia. | 1977 | 907912 |
| in vitro antibacterial activity and interactions with beta-lactamases and penicillin-binding proteins of the new monocarbam antibiotic u-78608. | u-78608, a new monocarbam antibiotic, was evaluated for in vitro activity against 312 clinical isolates of aerobic and anaerobic bacteria and subjected to several in vitro biochemical tests characterizing its interactions with beta-lactamases and penicillin-binding proteins (pbps). the antibacterial activity of the compound was compared directly with those of sq 83,360 (pirazmonam) and aztreonam. u-78608, sq 83,360, and aztreonam had generally poor activity against gram-positive aerobic bacteria ... | 1990 | 2193625 |
| evaluation of autoscan-w/a automated microbiology system for the identification of non-glucose-fermenting gram-negative bacilli. | we evaluated the ability of the autoscan-w/a (microscan division, baxter healthcare corporation, west sacramento, calif.), in conjunction with the dried colorimetric neg id type 2 panel (dcp) and new rapid fluorometric neg id panel (rfp), to identify non-glucose-fermenting gram-negative bacilli by challenging the system with 310 previously identified reference strains. of these 310 isolates, 286 organisms were in the dcp data base and 269 were in the rfp data base. use of the dcp panels resulted ... | 1990 | 2199522 |
| in vitro activity of ljc10,627, a new carbapenem antibiotic with high stability to dehydropeptidase i. | the in vitro activity of ljc10,627, a new carbapenem, was compared with those of imipenem and ceftazidime. ljc10,627 had broad-spectrum activity against gram-positive and gram-negative clinical isolates. the mics of this compound for 90% of members of the family enterobacteriaceae tested (mic90s), including strains resistant to ceftazidime, ranged from 0.1 to 25 micrograms/ml. ljc10,627 inhibited pseudomonas aeruginosa at an mic90 of 3.13 micrograms/ml; it thus was twofold more active than imipe ... | 1990 | 2203313 |
| in vitro activity of pd127,391, a new quinolone against bacterial isolates from cancer patients. | the in vitro activity of pd127,391, a new 4-quinolone, was compared to that of ciprofloxacin against common clinical bacterial isolates from patients with cancer. pd127,391 was found to have a broad antimicrobial spectrum with excellent activity against gram-positive isolates (including multidrug-resistant organism such as corynebacterium jeikeium, enterococcus faecalis, enterococcus faecium, methicillin-resistant staphylococcus aureus and coagulase-negative staphylococcus spp.). it was also ext ... | 1990 | 2209169 |
| in vitro antibacterial activity and beta-lactamase stability of the new carbapenem ljc10,627. | in in vitro susceptibility tests the new carbapenem ljc10,627 showed potent antibacterial activity against gram-positive and gram-negative bacteria, except that most methicillin-resistant staphylococcus aureus strains tested were found to be resistant to ljc10,627. ljc10,627 showed high activity against pseudomonas aeruginosa and was active against enterobacter cloacae and citrobacter freundii strains which were resistant to ceftazidime and cefpirome. the ki values of ljc10,627 for penicillinase ... | 1990 | 2209630 |
| presence of 3-o-methyl-l-xylose in the lipopolysaccharide of pseudomonas maltophilia n.c.t.c. 10257. | 3-o-methyl-l-xylose was isolated from whole cells of pseudomonas maltophilia n.c.t.c. 10257. the sugar is a component of lipopolysaccharide from which a polysaccharide also containing l-rhamnose and l-xylose was released by mild acid hydrolysis. 3-o-methyl-l-xylose was absent from five other strains of ps. maltophilia and one strain of pseudomonas geniculata. | 1977 | 869917 |
| nosocomial infections due to xanthomonas maltophilia (pseudomonas maltophilia) in patients with cancer. | from december 1985 to may 1986, xanthomonas maltophilia (formerly known as pseudomonas maltophilia) was isolated at an increased rate at our institution; 52 isolates of x. maltophilia were obtained in cultures of clinical specimens from 38 patients during that time. the records of 35 of these patients form the basis of this study. twelve (71%) of the 17 infected and nine (50%) of the 18 colonized patients had received or were receiving antimicrobial therapy. eleven of 17 patients (three of seven ... | 1990 | 2267495 |
| numerical analysis of 295 phenotypic features of 266 xanthomonas strains and related strains and an improved taxonomy of the genus. | an extensive phenotypic description and an improved classification and nomenclature of the genus xanthomonas are presented. a total of 266 strains obtained from different geographical areas, including representative strains of all species of the genus xanthomonas and most pathovars of xanthomonas campestris, as well as strains which might be genetically related to the genus xanthomonas, were examined for 295 morphological, biochemical, and physiological features. similarities among the strains w ... | 1990 | 2275852 |
| in vitro activity of hre 664, a penem antibiotic. | hre 664, a new penem antibiotic, inhibited 90% of escherichia coli, klebsiella, citrobacter diversus, proteus mirabilis, proteus vulgaris, salmonella, shigella, providencia, aeromonas, and morganella at less than or equal to 2 micrograms/ml but was considerably less active than cefotaxime, ceftazidime, and imipenem. it did not inhibit pseudomonas aeruginosa (mic greater than 128 micrograms/ml). hre 664 inhibited enterobacter spp., citrobacter freundii, and serratia marcescens at 1-8 micrograms/m ... | 1990 | 2279381 |
| comparative in vitro activities of newer quinolones against pseudomonas species and xanthomonas maltophilia isolated from patients with cancer. | the in vitro susceptibilities of three pseudomonas species (pseudomonas aeruginosa, pseudomonas putida, and pseudomonas fluorescens) and xanthomonas maltophilia to quinolone antimicrobial agents were determined. several newer agents, particularly pd117558, pd117596, pd127391, sparfloxacin (at-4140), a-56620, and temafloxacin, were active against pseudomonas species. x. maltophilia isolates were generally less susceptible than were pseudomonas isolates but were inhibited by some of the newer quin ... | 1990 | 2285297 |
| [susceptibility of clinically isolated bacterial strains to imipenem/cilastatin sodium]. | in vitro antibacterial activities of imipenem/cilastatin sodium (imipenem) and other beta-lactams against clinically isolated 353 bacterial strains were investigated. the results obtained in this study are summarized as follows: 1. imipenem (ipm) showed potent antibacterial activities against gram-positive cocci such as staphylococcus aureus, staphylococcus epidermidis, enterococcus faecalis, streptococcus agalactiae. 2. ipm had inferior or equivalent antibacterial activities to beta-lactams aga ... | 1990 | 2287059 |
| pseudomonas maltophilia causing heroin-associated infective endocarditis. | the association of pseudomonas maltophilia endocarditis in three patients with recent history of intravenous drug abuse is reported. all three patients had abnormal heart valves (two prosthetic and one rheumatic). a prominent characteristic of this uncommon pathogen is its in vitro resistance to the commonly used antimicrobials. cure was achieved in all three cases. in two cases, synergistic antibiotic combinations were used. in one case, plasmid-mediated resistance to amikacin sulfate (amikan, ... | 1978 | 718316 |
| aminoglycoside 6'-n acetyltransferase production by an isolate of pseudomonas maltophilia. | | 1978 | 690050 |
| puncture wound osteochondritis of the foot caused by pseudomonas maltophilia. | | 1990 | 2314954 |
| implications of beta-lactamase-inhibitor combinations. | resistance of many species of bacteria to beta-lactam antibiotics is mediated via inactivation by beta-lactamase. beta-lactamase inhibitors irreversibly bind to beta-lactamases and thus can prevent the destruction of active beta-lactam antibiotics. in the united states three beta-lactam-antibiotic/beta-lactam-inhibitor combinations are commercially available--the orally absorbed amoxicillin/clavulanic acid (a/c), the parenteral formulations of ampicillin/sulbactam (a/s) and ticarcillin/clavulana ... | 1990 | 2319514 |
| selective extraction of outer-membrane proteins from membrane complexes of pseudomonas maltophila by chloroform-methanol. | an organic phase partitioning method is described for the selective purification of outer-membrane proteins (omps) from the total membrane complex of the opportunistic human and sheep pathogen, pseudomonas maltophila. sds-page analysis confirmed that omps purified by chloroform-methanol treatment of the total membrane complex were not only identical to omps extracted from outer-membrane vesicles separated by sucrose gradient density centrifugation, but also possessed little or non-detectable lev ... | 1990 | 2336786 |
| [a method of isolating pseudomonas maltophilia from clinical specimens]. | | 1986 | 2434722 |
| serological classification of xanthomonas maltophilia (pseudomonas maltophilia) based on heat-stable o antigens. | twenty-six serotypes of xanthomonas maltophilia were defined by using 15 antisera described by hugh and ryschenkow (r. hugh and e. ryschenkow, j. gen. microbiol. 26:123-132, 1961) and 11 new antisera. the antisera were prepared by immunizing rabbits with bacterial strains heated at 100 degrees c for 2 h. twelve antisera required adsorptions with cross-reacting heterologous immunizing strains. we tested 275 clinical and environmental strains of x. maltophilia with 26 antisera by the slide aggluti ... | 1989 | 2473089 |
| polychlorinated biphenyl-degrading pseudomonads: survival in mouse intestines and competition with normal flora. | although naturally occurring and mutant organisms, historically, have been released into the environment for various purposes, health concerns associated with the release of microorganisms have recently resurfaced. federal agencies have been given the task of reassuring society that any released organisms are not likely to produce adverse health effects. methods, therefore, for evaluating the potential health effects due to environmental release of mutant and genetically engineered microorganism ... | 1989 | 2492348 |
| immunoelectron microscopic demonstration of an esterase on the outer membrane of xanthomonas maltophilia. | xanthomonas maltophilia (later synonym of pseudomonas maltophilia), an ubiquitous species, is known to show proteolytic and lipolytic activities. a cell-bound esterase which hydrolyzes beta-naphthyl acetate during growth has been extracted from a strain isolated from soil. because of its strongly hydrophobic character, the enzyme could be efficiently solubilized only by triton x-100. this nonionic detergent must be added in polyacrylamide gels to permit migration. polyclonal rabbit antibodies ra ... | 1989 | 2495761 |
| comparative in vitro activity of lomefloxacin, a new difluoroquinolone. | the in vitro activity of lomefloxacin, a new difluoroquinolone, was compared with that of norfloxacin, ciprofloxacin, gentamicin and ceftazidime against a total of 577 recent clinical isolates. mics were determined by a standard agar dilution procedure, and two inocula (10(4) and 10(6) cfu) were used throughout. lomefloxacin inhibited most species of the enterobacteriaceae, staphylococcus aureus (including methicillin-resistant strains) and haemophilus influenzae at less than or equal to 1 mg/l. ... | 1989 | 2498101 |
| isolation and characterization of monoclonal antibodies against alkaline phosphatase of pseudomonas aeruginosa. | monoclonal antibodies against the alkaline phosphatase of pseudomonas aeruginosa were produced from spleen cells of balb/c mice primed with purified alkaline phosphatase of p. aeruginosa atcc 10145 and sp20/ag-14 myeloma cells. the eight stable clones established produced antibodies that reacted by enzyme-linked immunosorbent and indirect immunofluorescence assays with all bacterial strains of p. aeruginosa, including the 17 serotypes and two nontypable strains. three of the clones cross-reacted ... | 1989 | 2501343 |
| species-specific interpretive breakpoints for ciprofloxacin disk diffusion susceptibility testing. | when ciprofloxacin was introduced on the swedish market the recommended interpretive standards for disk diffusion susceptibility testing using a 10 microgram disk were: sensitive greater than or equal to 24 mm (mic less than or equal to 1 mg/l) and resistant less than 18 mm (mic greater than 4 mg/l), except for enterococci where s greater than or equal to 18 mm and r less than 14 mm were recommended. a quality control study revealed that the accuracy of the routine susceptibility testing of cipr ... | 1989 | 2502836 |
| demonstration and partial characterization of adp-ribosylation in pseudomonas maltophilia. | adp-ribosylation of proteins occurs in many eukaryotes, and it is also the mechanism of action of a growing number of important bacterial toxins. to date, however, there is only one well-characterized adp-ribosylation system where the adp-ribosyltransferase and the substrate protein are both bacterial in origin, namely within the nitrogen-fixing bacterium rhodospirillum rubrum. the present paper demonstrates the endogenous adp-ribosylation of two proteins of mr 32,000 and 20,000 within pseudomon ... | 1989 | 2505752 |
| in vitro activity of pd 117596-2, a broad-spectrum difluoroquinolone. | the activity of pd 117596-2, a novel quinolone, was compared to that of other quinolones, ceftazidime, imipenem and gentamicin. pd 117596-2 inhibited most enterobacteriaceae at concentrations less than 0.25 micrograms/ml, being equal or superior in activity to ciprofloxacin and 2- to 4-fold more active than ofloxacin. it inhibited ceftazidime-resistant enterobacter spp., citrobacter spp. and serratia marcescens. the mic90 for pseudomonas aeruginosa, including strains with imipenem mics of 8 micr ... | 1989 | 2506029 |
| [susceptibility of clinical isolates to aztreonam]. | in vitro antibacterial activities of 9 antibiotics including aztreonam (azt) against clinically isolated gram-negative bacteria were determined using mic-2000 plus system. bacteria were isolated from clinical materials in saga medical school during a period from may 1987 to march 1988. summarized results were as follows: 1. azt showed excellent antibacterial activities against escherichia coli, klebsiella pneumoniae, proteus sp. and haemophilus influenzae, and mic80 values of azt against these o ... | 1989 | 2507799 |
| decreased outer membrane permeability in imipenem-resistant mutants of pseudomonas aeruginosa. | the outer membrane of imipenem-resistant mutants of pseudomonas aeruginosa was shown to have decreased permeability to imipenem but not to cephaloridine. these experiments were performed with intact cells and liposomes containing imipenem-hydrolyzing beta-lactamase derived from pseudomonas maltophilia, in both cases utilizing an imipenem concentration of 50 microm. in contrast, liposome swelling assays using imipenem at 8 mm detected no significant difference between the imipenem-resistant mutan ... | 1989 | 2508541 |
| in vitro and in vivo antibacterial activities of bo-1341, a new antipseudomonal cephalosporin. | bo-1341, a new antipseudomonal semisynthetic cephalosporin, was evaluated for in vitro and in vivo antibacterial activities in comparison with ceftazidime, cefotaxime, and cefoperazone. the in vitro activity of bo-1341 was generally superior or comparable to the activities of the reference antibiotics against clinical isolates of the family enterobacteriaceae. bo-1341 was highly active against pseudomonas aeruginosa (mic for 90% of the strains tested, 1.56 micrograms/ml), pseudomonas maltophilia ... | 1989 | 2510590 |
| in vitro antibacterial activity and beta-lactamase stability of the new carbapenem sm-7338. | the in vitro activity of the new carbapenem sm-7338 was tested in comparison with imipenem, ceftazidime, cefotaxime, flomoxef, cefuzonam and cefmetazole against 2850 clinical bacterial isolates. sm-7338 showed good activity against a broad spectrum of gram-positive and gram-negative bacteria. sm-7338 was very active against gram-negative bacteria, inhibiting all enterobacteriaceae, except 25% of serratia marcescens isolates, at a concentration of 0.78 mg/l. sm-7338 inhibited the majority of pseu ... | 1989 | 2512140 |
| pseudomonas maltophilia pseudosepticemia. | during a 17 month period, 25 hospitalized adult patients had blood cultures reported as positive for pseudomonas maltophila. review of the hospital records suggested that these were contaminants and that blood for coagulation studies and for cultures that were subsequently positive had been drawn simultaneously. the source of contamination appeared to be black-top evacuated collection tubes used for coagulation studies in adults. cultures of the liquid anticoagulant tubes yielded a pure growth o ... | 1978 | 637055 |
| a peptidyl dipeptidase-4 from pseudomonas maltophilia: purification and properties. | a peptidyl dipeptidase-4 (bacterial pdp-4) was purified to near homogeneity from a supernatant of pseudomonas maltophilia extracellular medium. bacterial pdp-4 is a single-polypeptide-chain enzyme, 82 kda, with an alkaline isoelectric point. peptides susceptible to hydrolysis by bacterial pdp-4 include angiotensin 1, bradykinin, enkephalins, atriopeptin 2, and smaller synthetic peptides. n-acylated tripeptides are hydrolyzed, but free tripeptides are not. a free carboxy terminus is required for ... | 1989 | 2539048 |
| comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate. | the in vitro activities of ticarcillin, piperacillin, clavulanic acid, tazobactam, ticarcillin-clavulanate, and piperacillin-tazobactam against 819 bacterial isolates were compared. the two beta-lactamase inhibitors, clavulanic acid and tazobactam, had little useful antibacterial activity but enhanced the activities of the penicillins against beta-lactamase-producing strains of haemophilus influenzae, branhamella catarrhalis, and methicillin-susceptible staphylococcus aureus; all strains were su ... | 1989 | 2552904 |
| distribution in clinical material and identification of pseudomonas maltophilia. | during the 10-year period ending march 1976, 128 (8.5%) of 1506 strains of gram-negative non-fermentative bacteria submitted to the national collection of type cultures for computer-assisted identification have been strains of pseudomonas maltophilia. these figures suggest that ps. maltophilia is both a relatively common species in clinical material in the united kingdom and also that many laboratories experience difficulty in identifying this species. we report the sources from which our strain ... | 1979 | 429581 |
| detection of essential arginine in bacterial peptidyl dipeptidase-4: arginine is not the anion binding site. | peptidyl dipeptidase-4 from pseudomonas maltophilia was modified with the arginine reagents p-hydroxyphenylglyoxal and 2,3-butanedione. the enzyme was inactivated in a pseudo-first-order manner by p-hydroxyphenylglyoxal with a half-time of 72 min. inactivation by 2,3-butanedione was biphasic with a rapid phase followed by a slower inactivation to less than 10% activity within 24h. the competitive inhibitor thiorphan protected against inactivation by phydroxyphenylglyoxal and by 2,3-butanedione a ... | 1989 | 2653317 |
| in vitro antibacterial activity of sm-7338, a carbapenem antibiotic with stability to dehydropeptidase i. | sm-7338, a new carbapenem antibiotic, was demonstrated to have potent antibacterial activity against a broad spectrum of aerobes, including staphylococcus aureus, beta-hemolytic streptococci, streptococcus pneumoniae, haemophilus influenzae, neisseria spp., members of the family enterobacteriaceae, pseudomonas spp., and gram-positive and gram-negative anaerobes in a collection of 1,102 unselected clinical isolates. at a concentration of 0.5 micrograms/ml, sm-7338 inhibited 90% of these strains. ... | 1989 | 2655530 |
| multicenter in vitro evaluation of sm-7338, a new carbapenem. | a new carbapenem, sm-7338, was compared with imipenem, cefotaxime, and ceftazidime at five medical centers. nearly 6,000 strains were tested by reference methods of the national committee for clinical laboratory standards, and sm-7338 inhibited the largest percentage of gram-negative bacilli. its spectrum included all members of the family enterobacteriaceae (99.7% were susceptible to less than or equal to 4 micrograms/ml), pseudomonas spp. (but not xanthomonas maltophilia), and acinetobacter sp ... | 1989 | 2658796 |
| [clinical experience of chemotherapy with cefmetazole for severe infections accompanying malignant hematological disorders]. | we made an attempt to treat with cefmetazole (cmz) 25 patients who developed severe infectious diseases while suffering with granulocytopenia associated with the treatment of malignant hematological disorders. 1. determination of bacteriological efficacy while 20 strains were isolated and identified from 15 patients, no significant bacteria were detected in 9 patients. isolates obtained were: 5 strains of enterococcus faecalis, 3 strains of haemophilus influenzae, 2 strains of staphylococcus epi ... | 1989 | 2664248 |
| [susceptibilities of clinical isolates to antibacterial agents. a study mainly focused on ofloxacin (the second report). reported by the research group for testing ofloxacin susceptibility on clinical isolates]. | susceptibilities of various clinical isolates to ofloxacin (oflx) and other antibacterial drugs were examined at 128 hospital laboratories in 36 prefectures throughout japan between april, 1986 and march, 1987. the results were totalized with an emphasis mainly on oflx and were compared with data obtained in the previous year. in this study, identification and susceptibility tests of the isolates were carried out at each hospital laboratory and the tests were performed according to the 1-dilutio ... | 1989 | 2664255 |
| [evaluation of a new semi-automatic method of identifying enterobacteriaceae, m.i.s.-enterobacteriaceae]. | m.i.s.-enterobacteriaceae is a new kit for identifying enterobacteriaceae using a microplate consisting of 21 biochemical characters with automated reading and interpretation. the validity of this method was studied by the identification of 350 strains of enterobacteria belonging to 44 species and comparison with the classical method of identification in test-tubes. results showed a diagnosis accuracy of 96 p. cent at the species level and 97.7 p. cent at the genus level. diagnosis accuracy reac ... | 1989 | 2665580 |
| laboratory survey of fluoroquinolone activity. | fluoroquinolones are active against a wide variety of bacteria. the antibacterial spectra of fluoroquinolones encompass staphylococci, bacillus species, and corynebacterium species implicated in infections of the immunocompromised host; enterobacteriaceae; most intestinal pathogens; and many gram-negative organisms commonly causing nosocomial infections. haemophilus influenzae, haemophilus ducreyi, neisseria gonorrhoeae, neisseria meningitidis, and branhamella catarrhalis are highly susceptible ... | 1989 | 2672262 |
| comparative in vitro activity of a new quinolone, am-1091. | the in vitro activity of a new quinolone, am-1091 [7-(3-amino-1-pyrrolidinyl)-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro- 4-oxo- 3-quinoline carboxylic acid hydrochloride], was compared with those of ciprofloxacin, ofloxacin, beta-lactams, and gentamicin. am-1091 inhibited 90% of the isolates of the family enterobacteriaceae at less than or equal to 0.12 micrograms/ml. for many species am-1091 was 2-fold more active than ciprofloxacin and 2- to 32-fold more active than ofloxacin. it inhibited e ... | 1989 | 2675753 |
| the barrier function of the outer membrane of pseudomonas maltophilia in the diffusion of saccharides and beta-lactam antibiotics. | this paper reports that the efficiency of solute diffusion through the outer membrane of pseudomonas maltophilia is roughly 3 to 5% of that of escherichia coli. this is despite the fact that the outer membrane pore(s) is only a little smaller than that of e. coli. these results suggest that p. maltophilia has a low copy number of porin(s). the outer membrane of antibiotic resistant clinical isolates showed even less efficient permeability towards saccharides and antibiotics than the laboratory s ... | 1989 | 2676712 |
| in vitro and in vivo activities of qa-241, a new tricyclic quinolone derivative. | the in vitro susceptibilities of 1,310 clinical isolates to qa-241, a novel tricyclic quinolone, were evaluated in comparison with susceptibilities to norfloxacin, ofloxacin, enoxacin, and ciprofloxacin. the mics of qa-241 for 90% of staphylococci, enterococcus faecalis isolates, and streptococcal species ranged from 1.56 to 6.25 micrograms/ml, and the activity of qa-241 was similar to those of norfloxacin and enoxacin but two to four times less potent than those of ofloxacin and ciprofloxacin. ... | 1989 | 2679369 |
| primary pseudomonas maltophilia infection of the lung. | to our knowledge, this is the first reported case of primary pseudomonas maltophilia pneumonia. presenting symptoms were fever and chills of two days' duration and a density in the right upper lobe. sputum culture showed normal flora, and multiple blood cultures were negative. antibiotic therapy initially with penicillin and then with carbenicillin was unsuccessful. selective bronchial aspiration yielded pure cultures of p maltophilia. when an appropriate antibiotic, chloramphenicol, was given, ... | 1979 | 419020 |
| therapeutic activity of meropenem in experimental infections. | meropenem and comparative antibiotics were evaluated in five models of infection. all antibiotics were administered parenterally; imipenem was used in combination with cilastatin but meropenem and other agents were given alone. generalized infections in mice caused by staphylococcus aureus, streptococcus pneumoniae, escherichia coli, serratia marcescens, proteus mirabilis or pseudomonas aeruginosa all responded to low doses of meropenem or imipenem. immunocompromised mice infected with ps. aerug ... | 1989 | 2681126 |
| purification and properties of a serine protease from pseudomonas matophilia. | the extracellular protease of pseudomonas maltophilia was partially purified by ammonium sulfate precipitation and chromatography on sephadex g-75 and bio-rex 70. gel electrophoresis revealed minor impurities. the enzyme exhibited the following properties: (i) molecular weight, 35,000; (ii) a see article; 10.8; (iii) isoelectric point, 9.3; (iv) ph optimum, 10.0; (v)s20, w equal 3.47. the enzyme was rapidly inactivated by ethylenediaminetetracetate, but activity could be partially restored with ... | 1975 | 234950 |
| intravenous/oral ciprofloxacin therapy versus intravenous ceftazidime therapy for selected bacterial infections. | the efficacy and toxicity of sequential intravenous and oral ciprofloxacin therapy was compared with intravenously administered ceftazidime in a prospective, randomized, controlled, non-blinded trial. thirty-two patients (16 patients receiving ciprofloxacin and 16 patients receiving ceftazidime) with 38 infections caused by susceptible pseudomonas aeruginosa, enteric gram-negative rods, salmonella group b, serratia marcescens, pseudomonas cepacia, and xanthomonas maltophilia at various sites wer ... | 1989 | 2686417 |
| production of an extracellular ribonuclease by pseudomonas maltophilia. | as part of a screening program for pseudomonad enzymes having an industrial interest, we selected ribonuclease (rnase) producing strains. of the 150 pseudomonads screened, 6 were found to produce an extracellular rnase activity when grown on solid medium. in broth culture, the rnase activity from these six species remained bound to the cells unless gelatin was added to the medium. gelatin was essential for the release of rnase in the broth culture, but the ph of the medium, addition of potential ... | 1979 | 36976 |
| comparative in vitro antibacterial activity of the new carbapenem meropenem (sm-7338). | the in vitro antimicrobial activity of the new carbapenem meropenem (sm-7338) was determined by an agar dilution method in comparison with imipenem, ticarcillin/calvulanic acid, ceftazidime and the fourth-generation cephalosporin cefepime (bmy 28142). meropenem showed superior activity against enterobacteriaceae (mic90 less than or equal to 0.06 mg/l) and against non-fermentative gram-negative rods, with the exception of xanthomonas maltophilia. meropenem had excellent activity against beta-lact ... | 1989 | 2695328 |
| isolation and characterization of thymidylate synthetase mutants of xanthomonas maltophilia. | thymidylate synthetase mutants of xanthomonas maltophilia atcc 13270 were isolated on a solid minimal medium containing 50 mg/l thymidine and a high concentration of trimethoprim (500 mg/l). it was found that a high concentration of trimethoprim was required to prevent background growth of the wild-type strain. the isolated mutants could grow on thymidine or dtmp at a concentration of 50 mg/l while they were unable to grow on 1000 mg/l thymine or 50 mg/l deoxyuridine. thymidylate synthetase acti ... | 1989 | 2705859 |
| antimicrobial activity of ro 41-1879, a new catechol cephalosporin. | the antimicrobial activity and spectrum of ro 41-1879, a new 7'-catechol substituted cephalosporin, was assessed in a broth microdilution system against 312 clinical isolates. ro 41-1879 demonstrated a slightly superior spectrum of activity (2- to 32-fold) compared to ceftazidime against gram-positive cocci, pseudomonas spp. and xanthomonas maltophilia. enterobacteriaceae strains were more susceptible (97% versus 96%) to ceftazidime at less than or equal to 16 micrograms/ml. these results repres ... | 1991 | 1819614 |
| studies on the microflora associated with xenic cultures of entamoeba gingivalis. | the microflora associated with xenic stock cultures (atcc 30927) of entamoeba gingivalis, the major protozoan of the human oral cavity, were isolated and identified as citrobacter diversus, yersinia enterocolitica, acinetobacter anitratus and pseudomonas maltophilia. in studies to determine whether the bacterial isolates were able to utilize rice starch as a sole carbon source, y. enterocolitica exhibited excellent growth in rice starch minimal medium and tysgm-9 medium (with rice starch), but g ... | 1989 | 2739589 |
| effect of media composition on the susceptibility of xanthomonas maltophilia to beta-lactam antibiotics. | the susceptibility of xanthomonas maltophilia strains to beta-lactams was shown to depend on the concentrations at which individual media were prepared. mic and disc susceptibility tests were performed on solidified mueller-hinton and iso-sensitest media prepared at 0.1, 0.3, 1, and 3 x the concentrations recommended by the manufacturers. nine of ten x. maltophilia strains tested showed increasing sensitivity to meropenem, cefotaxime, cefoperazone, piperacillin and latamoxef as the nutrient conc ... | 1991 | 1816181 |
| resistance of xanthomonas maltophilia to antibiotics and the effect of beta-lactamase inhibitors. | we examined the susceptibility of 50 isolates of xanthomonas maltophilia and the effect of beta-lactamase inhibitors upon the susceptibility. the majority of isolates were resistant to azlocillin, piperacillin, mezlocillin, ticarcillin, cefotaxime, ceftizoxime, ceftriaxone, cefoperazone, and ceftazidime. all isolates were resistant to imipenem, cgp 31608, aztreonam, and carumonam. although disk susceptibility tests showed that the combination of clavulanate with ticarcillin inhibited many isolat ... | 1989 | 2791491 |
| in vitro activity of me1228, a new parenteral cephalosporin. | me1228 is a new cephalosporin with an iminocarboxymethyl moiety on the acyl side chain and a novel pyridiniumthiomethyl group at position 3 of the bicyclic ring. its activity was compared with those of ceftazidime, imipenem, piperacillin, and gentamicin. me1228 inhibited most members of the family enterobacteriaceae, except for some enterobacter spp. and citrobacter freundii, at less than or equal to 0.25 micrograms/ml, and it inhibited gentamicin- and piperacillin-resistant isolates. it had mic ... | 1989 | 2802554 |
| comparative in-vitro activity of meropenem against clinical isolates including enterobacteriaceae with expanded-spectrum beta-lactamases. | meropenem, a new parenteral carbapenem, was tested in vitro by an agar-dilution method against 373 standard strains (aerobes and anaerobes) and against nine expanded-spectrum beta-lactamase-producing strains and their transconjugants (5 ctx-1, 2 caz-1, 2 caz-2). meropenem was compared with methicillin, imipenem, piperacillin, cefoxitin, cefotaxime, ceftazidime, gentamicin, chloramphenicol, clindamycin, ciprofloxacin, vancomycin and metronidazole. meropenem and imipenem exhibited an extended spec ... | 1989 | 2808205 |
| meropenem: activity against resistant gram-negative bacteria and interactions with beta-lactamases. | the activity of meropenem, a new carbapenem, was determined against 82 gram-negative bacteria in agar dilution tests. many of these isolates were resistant to one or more beta-lactam antibiotics and the mechanisms responsible for the resistance had been characterized. the production of beta-lactamases had little influence on susceptibility to either meropenem or imipenem except in tests with aeromonas hydrophila and pseudomonas (xanthomonas) maltophilia. these species produced metalloenzymes cap ... | 1989 | 2808207 |
| comparative in-vitro activity of meropenem on clinical isolates from the united kingdom. | mics of meropenem were determined for a wide range of common bacteria of clinical importance. for enterobacteriaceae, aeromonas spp., haemophilus influenzae, branhamella catarrhalis, neisseria gonorrhoeae, gardnerella vaginalis, campylobacter coli/jejuni, beta-haemolytic streptococci and anaerobes other than clostridium difficile, mics were almost always within the range 0.002-0.5 mg/l. the activity of meropenem for these organisms was always greater than that of imipenem and piperacillin, and w ... | 1989 | 2808214 |
| in-vitro activity of meropenem against clinical isolates obtained in canada. | the in-vitro activity of meropenem, a new parenteral carbapenem, was compared with that of imipenem, ceftazidime, cefotaxime, piperacillin, gentamicin and, where appropriate, other antibiotics against recent clinical isolates and characterized beta-lactamase producers. mics were determined by a standard agar dilution procedure and two inocula (10(4) and 10(6) cfu) were used throughout. meropenem inhibited 90% of isolates of escherichia coli, klebsiella pneumoniae, proteus mirabilis, indole-posit ... | 1989 | 2808216 |
| bacteriostatic and bactericidal in-vitro activity of meropenem against clinical isolates, including mycobacterium avium complex. | for clinical isolates the mics of meropenem were significantly lower than the mics of imipenem, especially against pseudomonas aeruginosa. furthermore, meropenem was bactericidal for pseudomonas spp., including ps. (xanthomonas) maltophilia, and staphylococci, with mbcs on average only two-fold above the respective mics. the bactericidal activity was confirmed by killing curve assays. strains with high meropenem mics (greater than or equal to 8 mg/l) were killed by a combination of the carbapene ... | 1989 | 2808217 |
| molecular cloning and expression of the imipenem-hydrolyzing beta-lactamase gene from pseudomonas maltophilia in escherichia coli. | the l-1 penicillinase structural gene, blas, from pseudomonas maltophilia was cloned into the vector pacyc184. the pmon01 recombinant plasmid selected by ampicillin resistance carried a 2.6-kilobase (kb) sau3a fragment of p. maltophilia dna and was confirmed to express l-1 beta-lactamase by comparative isoelectric focusing. a detailed physical map was constructed, and the blas structural gene was localized with a 17-mer oligonucleotide mixed probe encoding the l-1 nh2-terminal amino acid sequenc ... | 1988 | 2847278 |
| selective medium for isolation of xanthomonas maltophilia from soil and rhizosphere environments. | a selective medium (xmsm) was developed for isolation of xanthomonas maltophilia from bulk soil and plant rhizosphere environments. the xmsm basal medium contained maltose, tryptone, bromthymol blue, and agar. antibiotics added to select for x. maltophilia were cycloheximide, nystatin, cephalexin, bacitracin, penicillin g, novobiocin, neomycin sulfate, and tobramycin. a comparison was made between xmsm and 1/10-strength tryptic soy broth agar for recovery of x. maltophilia from sterile and nonst ... | 1989 | 2930173 |
| in vitro evaluation of a-56619 and a-56620, two new quinolones. | the in vitro activities of two new aryl-fluoroquinolones (a-56619 and a-56620) were compared with those of ciprofloxacin, ofloxacin, enoxacin, and norfloxacin. all six quinolones had broad spectra of antibacterial activity; the streptococci, pseudomonas maltophilia, and pseudomonas cepacia were the least susceptible. a-56619, a-56620, and chloramphenicol had similar activity against anaerobic bacteria. with both drugs, a low frequency of resistant variants (less than 10(-8)) was observed. by reg ... | 1986 | 2942099 |
| identification and characterisation of pmaci an endonuclease of novel specificity from pseudomonas maltophila. | we report the use of monoq fplc (fast protein liquid chromatography) for the rapid purification of a novel type ii restriction endonuclease pmaci, from pseudomonas maltophila, which recognises the sequence 5'-cac decreases gtg-3'. the resulting enzyme is free of other nucleases to a level suitable for its characterisation by multiple-substrate digestion and dna sequencing techniques. this method appears to be widely applicable and we have used it for the isolation of restriction endonucleases of ... | 1986 | 3005970 |
| in vitro susceptibility of 33 clinical case isolates of xanthomonas maltophilia. inconsistent correlation of agar dilution and of disk diffusion test results. | xanthomonas maltophilia is an emerging nosocomial pathogen, possibly selected by a changing antimicrobial usage and patient population. in the present study, we tested the susceptibility of 33 recent clinical case isolates to 12 commonly employed antimicrobials. trimethoprim-sulfamethoxazole (1:19 ratio) and doxycycline were uniformly the most active agents; ciprofloxacin and fleroxacin were slightly less active and, along with tetracycline and ceftazidime, more variable in their potency. intere ... | 1991 | 1797460 |
| cloning and expression of the imipenem-hydrolyzing beta-lactamase operon from pseudomonas maltophilia in escherichia coli. | the l-1 penicillinase structural gene, blas, from pseudomonas maltophilia has been cloned into the vector pacyc184. the pmon01 recombinant plasmid selected by ampicillin resistance carried a 2.6-kilobase sau3a fragment of p. maltophilia dna and was confirmed to express l-1 beta-lactamase by comparative isoelectric focusing. a detailed physical map was constructed, and the blas structural gene was localized with a 17-mer oligonucleotide mixed probe encoding the l-1 n-terminal amino acid sequence. ... | 1988 | 3046482 |
| [bacterial infection agents in hospitalized patients]. | during six months the pattern of microbial isolates has been analysed from 1492 urinary tract infections, from 1445 wound infections, from 451 bronchial secretions, from 3067 blood cultures, from 116 peritoneal swabs and from 39 cerebrospinal fluids. all the specimens investigated were taken from patients of surgical, neurosurgical, internal wards and two intensive care units. in total, the most frequent isolates were grampositive microorganisms like staphylococus aureus, straphylococcus epiderm ... | 1986 | 3107262 |
| antibiotic susceptibility and outer membrane proteins of clinical xanthomonas maltophilia isolates. | twenty clinical xanthomonas maltophilia isolates were studied for their susceptibility to various antibiotics and for their outer membrane protein profiles and compared to pseudomonas aeruginosa isolates. among the antibiotics studied, fleroxacin and ciprofloxacin exhibited the greatest activity (mic90 4 micrograms/ml). all the x. maltophilia isolates exhibited similar outer membrane protein profiles with 40, 23 and 21 major proteins, whereas the outer membrane of p. aeruginosa revealed at least ... | 1991 | 1790722 |
| qualitative and quantitative microbiological analysis of sputa of 102 patients with cystic fibrosis. | a microbiological analysis of 102 patients suffering from cystic fibrosis was conducted over a 22 month period. 20 microbial species with the following incidence were identified: pseudomonas aeruginosa: 83.4%; candida albicans: 29.4%; staphylococcus aureus: 24.5%; staphylococcus epidermidis: 11.8%; haemophilus influenzae: 11.8%; streptococcus pneumoniae; 6.9%; pseudomonas maltophilia: 6.8%; aspergillus fumigatus: 5.9%. other species were present in less than 5% of the patients. in the majority o ... | 1987 | 3117700 |
| [automated micromethod for the determination of the utilization of carbon sources by clinically significant pseudomonas species]. | the assimilation of 43 different carbon substrates by 93 clinical strains of pseudomonas aeruginosa was studied by a new miniaturized rapid method. reading of assimilation results was done photometrically after 18-20 h incubation and the resulting data were captured and stored by a microcomputer. the differentiating capacity of the assimilation tests were verified by comparing the results of 41 strains of pseudomonas fluorescens, 48 strains of pseudomonas putida, 52 strains of pseudomonas maltop ... | 1987 | 3118596 |
| in vitro activity of e-1040, a novel cephalosporin with potent activity against pseudomonas aeruginosa. | the in vitro activity of e-1040 [(6r,7r)-3-[(4-carbamoyl-1-quinuclidinio)methyl]-7-[2-(5-amino-1,2 ,4- thiadiazol-3-yl)-(z)-2-methoxyiminoacetoamido]-8-oxo-5-thia- 1- azabicyclo(4,2,0)oct-2-ene-2-carboxylate], a novel cephalosporin, was compared with that of ceftazidime, cefpirome, cefepime, imipenem, and gentamicin. e-1040 inhibited 50% of members of the family enterobacteriaceae, pseudomonas aeruginosa, and haemophilus and neisseria species at less than or equal to 0.25 microgram/ml, and the m ... | 1988 | 3150915 |
| ciprofloxacin disk susceptibility tests: interpretive zone size standards for 5-microgram disks. | evaluations of 5-microgram ciprofloxacin disk diffusion susceptibility tests were performed independently by seven different investigators. the results of the separate tests were combined to increase the number of resistant strains in the challenge set of microorganisms. based on data with 2,652 isolates, the following interpretive breakpoints are tentatively proposed for use in ongoing clinical trials of ciprofloxacin: less than or equal to 15 mm, resistant (mic greater than 2.0 micrograms/ml); ... | 1985 | 3159749 |
| [susceptibility of gram-negative bacterial isolates to six beta-lactam and two aminoglycoside antibiotics at our university hospital]. | susceptibilities of gram-negative bacterial strains isolated at the university hospital in 1987 to six beta-lactam antibiotics (azthreonam cefmetazole, ceftizoxime, latamoxef, aminobenzyl-penicillin and piperacillin) and two aminoglycoside antibiotics (gentamicin and amikacin) were examined by agar dilution and the agar diffusion method. results obtained from both methods correlated well in most of the strains. most of the strains belonging to escherichia coli, klebsiella oxytoca, klebsiella pne ... | 1988 | 3175388 |
| gaps and perspectives of new fluoroquinolones. | the gaps in the present piperazinyl-substituted fluoroquinolones include: (a) gaps in their antibacterial spectrum, varying from one fluoroquinolone to another for streptococci-pneumococci-enterococci (spe), some gram-negative and gram-positive anaerobes, nocardia, pseudomonas maltophilia, ureaplasma urealyticum, slow-growing mycobacteria; (b) a ph dependence of their antibacterial activity (low activity at acidic ph for piperazinyl-substituted fluoroquinolones); (c) a rapid development of bacte ... | 1988 | 3215107 |
| [a clinical evaluation of sultamicillin fine granules in the treatment of meibomianitis]. | this study was performed to evaluate the clinical efficacy and the safety of sultamicillin (sbtpc) fine granules in the treatment of patients with meibomianitis. a dose of 375 mg sbtpc granules was orally given to 10 patients with meibomianitis after each meal, three times a day. the results obtained are summarized as follows. efficacies were rated as good in 7 cases, fair in 2 and poor in 1 with an efficacy ratio of 70.0%. no side effects were observed throughout the study. the organisms isolat ... | 1988 | 3249376 |
| [effect of cyclic nucleotides on beta-lactamase production and outer membrane proteins of clinical xanthomonas maltophilia isolates]. | resistance of clinical xanthomonas maltophilia isolates to beta-lactam compounds is influenced considerably by the nutrient medium employed for sensitivity testing; the organisms were much more resistant to beta-lactams when susceptibility testing was performed in mueller-hinton broth as compared to isosensitest broth as the nutrient medium. consequently, the influence of cyclic nucleotides was studied on beta-lactamase expression and outer membrane proteins in more detail. the exogenous supply ... | 1991 | 1648031 |
| prevalence of serotypes of xanthomonas maltophilia from world-wide sources. | since its development in 1988, a serologic typing scheme for xanthomonas maltophilia, based on 31 o antigens, has been successfully used to serotype isolates involved in nosocomial outbreaks in the united states. to determine if this serotyping scheme would be useful in typing x. maltophilia isolates from world-wide sources, we obtained additional isolates from 10 countries; of 900 isolates tested, 795 (88.3%) were typable. in order of predominance, the three most common serotypes were 10, 3 and ... | 1992 | 1582474 |
| outer membrane permeability and beta-lactamase content in pseudomonas maltophilia clinical isolates and laboratory mutants. | low outer-membrane permeability appears to be responsible for the generally high degree of antibiotic resistance of pseudomonas maltophilia. constitutive overproduction of beta-lactamases affects the sensitivity of these bacteria only to those beta-lactam antibiotics that are hydrolyzed by strain-specific beta-lactamases and that do not efficiently induce these enzymes in inducible strains. | 1988 | 3263685 |
| comparative activity of the 4-quinolones. | minimal inhibitory concentrations (mics) of the 4-quinolones ciprofloxacin, enoxacin, norfloxacin, ofloxacin, pefloxacin, difloxacin, a-56620, and ci-934 are consistent world-wide, with allowances for differences in acquired resistance. mics of these drugs for enterobacteriaceae correlate with those of nalidixic acid, but resistance to the quinolones is rare if a breakpoint of greater than 2 mg/l is accepted. most intestinal pathogens are sensitive. acinetobacter, pseudomonas aeruginosa, and oth ... | 1988 | 3279501 |
| sterility and efficiency of two methods of cardiac output determination: closed loop and capped syringe methods. | a prospective randomized study was done to compare the fluid contamination rates of two methods used to determine cardiac output by thermodilution under in-use conditions. fifty patients were randomly assigned to have cardiac output measured by the capped syringe or closed loop method, and were followed with quantitative cultures of fluid and catheter. the two treatment groups (n = 25 each) were comparable in terms of age, sex, intensive care unit location, underlying diagnosis, and mean number ... | 1988 | 3280519 |
| comparative in vitro activity of a new fluorinated 4-quinolone, t-3262 (a-60969). | the in vitro activity of a new quinolone, t-3262 [a-60969; dl-7-(3-amino-1-pyrrolidinyl)-1-(2,4-difluorophenyl)-6-fluoro-1-, 4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid monohydrate], was compared with those of ciprofloxacin, ofloxacin, ceftazidime, imipenem, and gentamicin. t-3262 inhibited 90% of isolates of the family enterobacteriaceae at a concentration of less than or equal to 0.25 micrograms/ml. it was two to four times more active than ofloxacin and similarly or slightly less acti ... | 1988 | 3293524 |
| pseudomonas maltophilia. | | 1987 | 3294701 |
| in vitro activity and beta-lactamase stability of a new monobactam, b0-1165. | b0-1165 is a 1-carboxy-1-cyclopropoxyamino,4-fluoromethyl monobactam. it inhibited the majority of escherichia coli, klebsiella pneumoniae, klebsiella oxytoca, citrobacter diversus, aeromonas hydrophila, proteus mirabilis, proteus vulgaris, providencia rettgeri, providencia stuartii, yersinia enterocolitica, haemophilus influenzae, neisseria gonorrhoeae, and salmonella and shigella species at less than or equal to 0.125 microgram/ml. overall, its in vitro activity was similar to that of aztreona ... | 1987 | 3300528 |
| serological studies in crohn's disease. | elisa and immunofluorescence tests were carried out on sera from patients with crohn's disease and ulcerative colitis. the results indicate that mean antibody levels to yersinia enterocolitica types o:9 and o:3 and klebsiella pneumoniae, but not pseudomonas maltophilia, are significantly higher in these patients than in control subjects. there are differing antibody levels in ileal and colonic disease, and there is a significant fall in antibody levels 9-12 months after remission from clinical s ... | 1987 | 3305007 |
| [comparative activity of ticarcillin-clavulanic acid and various beta-lactams against pseudomonas maltophilia]. | an increase is observed in the isolation of p. maltophilia as a casual agent of nosocomial infection, particularly in hospitalized immunocompromised patients. these infections are associated with the acute problem of their treatment as most of the p. maltophilia strains are generally resistant to many of the commonly used antimicrobial agents, including those active against pseudomonas aeruginosa: beta lactams, aminoglycosides and imipenem. this resistance is correlated with two inducible beta l ... | 1987 | 3309818 |
| in vitro and in vivo antibacterial activities of cs-807, a new oral cephalosporin. | cs-807 is a new oral prodrug of r-3746, a cephalosporin derivative, with potent in vitro and in vivo antibacterial activity against both gram-positive and gram-negative bacteria. the susceptibility of about 1,200 clinical isolates to r-3746 was determined by the agar dilution method. ninety percent or more of pathogens such as staphylococcus aureus, streptococci, escherichia coli, klebsiella pneumoniae, klebsiella oxytoca, indole-positive and indole-negative proteus spp., providencia rettgeri, a ... | 1987 | 3310868 |
| in vitro antibacterial activity and beta-lactamase stability of cl 118523, an aminothiazolyl iminomethoxy cephalosporin. | cl 118523 is an aminothiazolyl cephalosporin which contains a 1, 2, 3-thiadiazol radical at position 3 of the cephem nucleus. it was as active as cefotaxime, ceftazidime and aztreonam against most enterobacteriaceae, mic 90% less than 1 mg/l, and more active, 8 to 32-fold, than cefoperazone and cefoxitin. enterobacter species resistant to the other agents were resistant to cl 118523. cl 118523 did not inhibit pseudomonas aeruginosa, pseudomonas maltophilia, mic greater than 128 mg/l. it had exce ... | 1987 | 3322588 |
| a bacterial binding site which binds human chorionic gonadotropin but not human luteinizing hormone. | exposed sites on pseudomonas maltophilia (atc #1637), which bind both human chorionic gonadotropin (hcg) and a native hcg-like ligand with equal high affinity, are described. this high-affinity binding site (kd = 1.3 x 10(-10) binds hcg, but does not bind human luteinizing hormone (hlh), nor related human glycoprotein hormones, thyrotropin, and follicle stimulating hormone. a lower affinity, 2.3 x 10(-9), is also described which binds hlh and hcg equally well. this is the first description of a ... | 1992 | 1576977 |
| [role of pseudomonas maltophilia and "pseudomonas like bacteria group va" in the etiology of crohn disease]. | in 1976, parent and mitchell isolated cell-wall defective bacteria of the species pseudomonas maltophilia and pseudomonas like bacteria group va from resected bowel tissue of 8 consecutively operated patients with crohn's disease. the control group, which included patients with ulcerative colitis, was negative in this respect. the isolated strains were available for our own investigations. new zealand white rabbits were inoculated with killed bacteria to produce specific antisera. frozen section ... | 1987 | 3326308 |
| in vitro activities of ici 194008 and ici 193428, two new cephem antimicrobial agents. | the in vitro activities of two new cephem antibiotics, ici 193428 and ici 194008, were compared with those of cefpirome, cefotaxime, ceftazidime, and piperacillin. essentially all strains of the family enterobacteriaceae were inhibited by both study drugs at concentrations of less than or equal to 4 micrograms/ml. both new cephems were comparable to ceftazidime against pseudomonas aeruginosa (mic for 90% of strains, 8 micrograms/ml) and were the most active agents tested against pseudomonas malt ... | 1987 | 3326527 |
| injury from silage wagon accident complicated by mucormycosis. | infection due to farm machinery injuries may be caused by microorganisms found in soil or decaying vegetable material. a case of injury due to entrapment of a young boy in a silage wagon is reported here. his injuries were complicated by infection with aspergillus species, absidia species, rhizopus species (the latter two are members of the mucorales order), and pseudomonas maltophilia. successful treatment of his infection followed aggressive surgical debridement of the anterior abdominal wall, ... | 1988 | 3385836 |
| pseudomonas septicemia due to deficient disinfectant mixing during reuse. | we describe a cluster of four septicemias with pseudomonas, that occurred in a unit performing formaldehyde reuse of capillary dialyzers. samples of blood, heparin solutions, dialysate and effluent of reused dialyzers, were evaluated bacteriologically and upon the adequacy of the reuse procedure. pseudomonas aeruginosa, vesicularis and/or xanthomonas maltophilia were found on the blood cultures obtained during the septicemic reactions, and in the effluent of two reprocessed dialyzers not yet use ... | 1992 | 1551723 |
| synergistic interactions of ciprofloxacin and extended-spectrum beta-lactams or aminoglycosides against multiply drug-resistant pseudomonas maltophilia. | the susceptibility of 28 clinical isolates of pseudomonas maltophilia to 16 antimicrobial agents was determined in vitro by a standard agar dilution method with inoculum sizes of 10(4) and 10(6) cfu. all isolates exhibited multiple drug resistance. nine isolates were selected for studies of combinations of ciprofloxacin with seven antipseudomonal beta-lactams and three aminoglycosides by a checkerboard agar dilution technique. synergistic or additive combinations of ciprofloxacin in clinically a ... | 1988 | 3395107 |
| partial characterization of the 30 kd ig-binding protein from pseudomonas maltophilia. | we have previously demonstrated that pseudomonas maltophilia (atcc 13637) possess a 30 kda cell wall protein which binds various subclasses of igg's and iga by their fc region. the protein was solubilized by papain and purified by affinity chromatography on cyanogen bromide activated sepharose beads conjugated with human igg. the eluent was electrophoresed on a 12% polyacrylamide gel under denaturing conditions, and the immunoactive bands identified by western blot analysis, a second gel was sta ... | 1992 | 1540156 |
| [study of specific hcg binding to pseudomonas maltophilia]. | | 1987 | 3449421 |
| in vitro activity of ci-934 compared with ciprofloxacin, enoxacin, norfloxacin, and vancomycin. | the in vitro activity of the quinolone ci-934 was compared with ciprofloxacin, norfloxacin, enoxacin, and vancomycin against 607 gram-positive and -negative isolates. ci-934 inhibited 90% of the enterobacteriaceae, aeromonas hydrophila, and acinetobacter spp. at 1 microgram/ml. decreased activity was observed against pseudomonas aeruginosa. pseudomonas maltophilia, and other pseudomonas spp. with ci-934 mic90 greater than or equal to 8 micrograms/ml. ci-934 activity against gram-positive organis ... | 1987 | 3472704 |